Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Hosted on MSN22h
How to Play NVO Stock After New Drug's Success in Obesity Study
Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...
The Pharma Letter2h
BioAge rings the changes after azelaprag failure
A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...
GlobalData on MSN22h
GLP-1RA developer Metsera targets $289m IPO
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
BMJ6h
Ozempic babies: are weight loss drugs leading to unintended pregnancies?
Posts about unexpected pregnancies while using drugs such as Ozempic for weight loss are trending on social media. Does any scientific evidence back this up? Sangeetha Nadarajah reports Amid the ...